Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 4/2015

01.04.2015 | Antiphospholipid Syndrome (D Erkan, Section Editor)

Pediatric Antiphospholipid Syndrome

verfasst von: Cassyanne L. Aguiar, Arzu Soybilgic, Tadej Avcin, Barry L. Myones

Erschienen in: Current Rheumatology Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Antiphospholipid syndrome (APS) is a multisystem autoimmune condition characterized by vascular thromboses associated with persistently positive antiphospholipid antibodies. There is currently a paucity of data (incidence, prevalence, thrombosis risk, and effective treatment) in pediatric APS. The purpose of this report is to review the current literature on APS in children and neonates, identify the gaps in current knowledge, and suggest avenues for studies to fill those gaps.
Literatur
1.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.PubMed
2.
Avcin T, Ambrozic A, Kuhar M, et al. Anticardiolipin and anti-beta(2) glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology (Oxford). 2001;40(5):565–73.
3.
Berkun Y, Simchen M, Strauss T, et al. Antiphospholipid antibodies in neonates with stroke–a unique entity or variant of antiphospholipid syndrome? Lupus. 2014;23(10):986–93.PubMed
4.
Avcin T, Toplak N. Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep. 2007;9(3):212–8.PubMed
5.
Gharavi AE, Pierangeli SS, Espinola RG, et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 2002;46(2):545–52.PubMed
6.
Gharavi AE, Pierangeli SS. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus. 1998;7 Suppl 2:S52–4.PubMed
7.
Gharavi AE, Vega-Ostertag M, Espinola RG, et al. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus. 2004;13(1):17–23.PubMed
8.
Wenzel C, Stoiser B, Locker G, et al. Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med. 2002;30(4):763–70.PubMed
9.
Cruz-Tapias P, Blank M, Anaya JM, et al. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012;24(4):389–93.PubMed
10.
Blank M, Israeli E, Shoenfeld Y. When APS (Hughes syndrome) met the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Lupus. 2012;21(7):711–4.PubMed
11.
Andreoli L, Nalli C, Motta M, et al. Anti-B2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? Ann Rheum Dis. 2011;70(2):380–3.PubMed
12.
Wahezi DM, Ilowite NT, Wu XX, et al. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I. Lupus. 2013;22(7):702–11.PubMedCentralPubMed
13.
Guerin J, Casey E, Feighery C, et al. Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity. 1999;31(2):109–16.PubMed
14.
Kumar S, Papalardo E, Sunkureddi P, et al. Isolated elevation of IgA anti-Beta2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus. 2009;18(11):1011–4.PubMed
15.
Samarkos M, Davies K, Gordon C, et al. Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol. 2006;25(2):199–204.PubMed
16.
Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714–8.PubMed
17.
Erkan D, Lockshin M. High risk antiphospholipid antibody profile: matter of the number or titer of tests? E-letter to the editor (re: Incidence of first thrombembolic event in asymptomatic carries of high-risk aPL profile: a multicenter prospective study, Pengo et al. Blood 2011;17:4714). Published online on 24 January 2012, available at: http://​bloodjournal.​hematologylibrar​y.​org/​letters.
18.
Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827–32.PubMed
19.
Pengo V, Biasiolo A, Gresele P, et al. Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost. 2007;5(5):925–30.PubMed
20.
Nakashima MO, Rogers HJ. Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants. Blood Res. 2014;49(2):85–94.PubMedCentralPubMed
21.
Thornburg C, Pipe S. Neonatal thromboembolic emergencies. Semin Fetal Neonatol Med. 2006;11(3):198–206.
22.
Male C, Lechner K, Eichinger S, et al. Clinical significance of lupus anticoagulants in children. J Pediatr. 1999;134(2):199–205.PubMed
23.
Flanders MM, Crist RA, Roberts WL, et al. Pediatric reference intervals for seven common coagulation assays. Clin Chem. 2005;51(9):1738–42.PubMed
24.••
Avcin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics. 2008;122(5):e1100–7. Most comprehensive descriptive characteristics of pediatric APS from an international registry. PubMed
25.
Sanna G, Bertolaccini ML, Hughes GR. Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology. Ann N Y Acad Sci. 2005;1051:465–86.PubMed
26.
Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost. 1995;74(1):415–25.PubMed
27.
Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83(5):1251–7.PubMed
28.
Motta M, Chirico G, Rebaioli CB, et al. Anticardiolipin and anti-beta2 glycoprotein 1 antibodies in infants born to mother with antiphospholipid antibody-positive autoimmune disease: a follow-up study. Am J Perinatol. 2006;23(4):247–51.PubMed
29.
Garty BZ, Ludomirsky A, Danon YL, et al. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol. 1994;1(6):667–9.PubMedCentralPubMed
30.
Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.PubMedCentralPubMed
31.
Samarkos M, Davies KA, Gordon C, et al. IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations. Rheumatology (Oxford). 2001;40(9):1026–32.
32.
Sammaritano LR, Ng S, Sobel R, et al. Anticardiolipin IgG subclases. Association of IgG2 with arterial and/or venous thrombosis. Arthritis Rheum. 1997;40(11):1998–2006.PubMed
33.
Boffa MC, Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibodies: a review. Lupus. 2007;16(8):634–41.
34.
Peixoto MV, de Carvalho JF, Rodrigues CE. Clinical, laboratory, and therapeutic analyses of 21 patients with neonatal thrombosis and antiphospholipid antibodies: a literature review. J Immunol Res. 2014;2014:672603.PubMedCentralPubMed
35.
Boffa MC, Aurousseau MH, Lachassinne E, et al. European register of babies born to mothers with antiphospholipid syndrome. Lupus. 2004;13(9):713–7.PubMed
36.
Boffa MC, Lachassinne E, Boinot C, et al. European registry of babies born to mothers with antiphospholipid syndrome: a result update. Lupus. 2009;18(10):900–4.PubMed
37.
Mekinian A, Carbillon L, Nicaise-Roland P, et al. Mothers’ antiphospholipid antibodies during pregnancy and the relation to offspring outcome. Clin Exp Rheumatol. 2014;32(3):446.PubMed
38.•
Mekinian A, Lachassinne E, Nicaise-Roland P, et al. European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis. 2013;72(2):217–22. A prospective study aiming to describe the long-term outcomes of children born to mothers with antiphospholipid syndrome. PubMedCentralPubMed
39.
Nalli C, Iodice A, Andreoli L, et al. The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes. Lupus. 2014;23(6):507–17.PubMed
40.
Ross G, Sammaritano L, Nass R, et al. Affects of mother’s autoimmune disease during pregnancy on learning disabilities and hand preference in their children. Arch Pediatr Adolesc Med. 2003;157(4):397–402.PubMed
41.
Brewster JA, Shaw NJ, Farquharson RG. Neonatal and pediatric outcome of infants born to mothers with antiphospholipid syndrome. J Perinat Med. 1999;27(3):183–7.PubMed
42.
Nacinovich R, Galli J, Bomba M, et al. Neuropsychological development of children born to patients with antiphospholipid syndrome. Arthritis Rheum. 2008;59(3):345–51.PubMed
43.
Abisror N, Mekinian A, Lachassinne E, et al. Autism spectrum disorders in babies born to mothers with antiphospholipid syndrome. Semin Arthritis Rheum. 2013;43(3):348–51.PubMed
44.•
Gordon O, Almagor Y, Fridler D, et al. De novo neonatal antiphospholipid syndrome: a case report and review of the literature. Semin Arthritis Rheum. 2014;44(2):241–5. A recent review of de novo neonatal APS. PubMed
45.
Hansen K, Kong D, Moore K, et al. Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol. 2001;28(9):2018–24.PubMed
46.
Hudson M, Herr AL, Rauch J, et al. The presence of multiple prothromboitc risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol. 2003;30(11):2385–91.PubMedCentralPubMed
47.
Rosendaal F, Siscovick D, Schwartz SM, et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood. 1997;89(8):2817–21.PubMed
48.
Giron-Gonzalez J, Garcia del Rio E, Rodriguez C, et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol. 2004;31(8):1560–7.
49.
Kaul M, Erkan D, Sammaritano L, et al. Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheum Dis. 2007;66(7):927–30.PubMedCentralPubMed
50.
Tolbert J, Carpenter SL. Common acquired causes of thrombosis in children. Curr Probl Pediatr Adolesc Health Care. 2013;43(7):169–77.PubMed
51.
Avcin T, Cimaz R, Rozman B, Ped-APS Registry Collaborative Group. The Ped-APS registry: the antiphospholipid syndrome in childhood. Lupus. 2009;18(10):894–9.PubMed
52.
Albisetti M, Moeller A, Waldvogel K, et al. Congenital prothrombotic disorders in children with peripheral venous and arterial thromboses. Acta Haematol. 2007;117(3):149–55.PubMed
53.
Revel-Vilk S, Chan A, Bauman M, et al. Prothrombotic conditions in an unselected cohort of children with venous thromboembolic disease. J Thromb Haemost. 2003;1(5):915–21.PubMed
54.
Yang JY, Chan AK. Pediatric thrombophilia. Pediatr Clin North Am. 2013;60(6):1443–62.PubMed
55.•
Kenet G, Aronis S, Berkun Y, et al. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost. 2011;37(7):802–9. A meta-analysis describing the impact of antiphospholipid antibodies on the risk of thrombotic events in children.
56.
Manco-Johnson MJ, Nuss R. Lupus anticoagulant in children with thrombosis. Am J Hematol. 1995;48(4):240–3.PubMed
57.
Tavil B, Ozyurek E, Gumruk F, et al. Antiphospholipid antibodies in Turkish children with thrombosis. Blood Coagul Fibrinolysis. 2007;18(4):347–52.PubMed
58.
Muscal E, Brey RL. Antiphospholipid syndrome and the brain in pediatric and adult patients. Lupus. 2010;19(4):406–11.PubMedCentralPubMed
59.
Lampropoulos CE, Koutroumanidis M, Reynolds PP, et al. Electroencephalography in the assessment of neuropsychiatric manifestation in antiphospholipid syndrome and systemic lupus erythematosus. Arthritis Rheum. 2005;52(3):841–6.PubMed
60.
Biernacka-Zielinska M, Lipinska J, Szymanska-Kaluza J, et al. Recurrent arterial and venous thrombosis in a 16-year-old boy in the course of primary antiphospholipid syndrome despite treatment with low-molecular-weight heparin: a case report. J Med Case Rep. 2013;7:221.PubMedCentralPubMed
61.
Brogna C, Mariotti P, Manna R. Conventional and intravenous immunoglobulin therapy in paediatric antiphospholipid antibodies-related chorea. Lupus. 2014;23:1449–51.PubMed
62.
Avcin T, Benseler SM, Tyrrell PN, et al. A followup study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis Rheum. 2008;59(2):206–13.PubMed
63.
Harel L, Sandborg C, Lee T, et al. Neuropsychiatric manifestations in pediatric systemic lupus erythematosus and association with antiphospholipid antibodies. J Rheumatol. 2006;33(9):1873–7.PubMed
64.
von Scheven E, Glidden DV, Elder ME. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2002;47(4):414–20.
65.
Cimaz R, Romeo A, Scarano A, et al. Prevalence of anti-cardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia. 2002;43(1):52–9.PubMed
66.
Constantin T, Kálovics T, Ponyi A, et al. Prevalence of antiphospholipid and antinuclear antibodies in children with epilepsy. Med Sci Monit. 2009;15(4):CR164–9.PubMed
67.
Avčin T, Markelj G, Nikšič V, et al. Estimation of antiphospholipid antibodies in a prospective longitudinal study of children with migraine. Cephalalgia. 2004;24(10):831–7.
68.
Lampropoulos CE, Hughes GR. The antiphospholipid (Hughes’) syndrome: changing the face of neurology. Eur J Intern Med. 2004;15(3):147–50.PubMed
69.
Careaga M, Hansen RL, Hertz-Piccotto I, et al. Increased anti-phospholipid antibodies in autism spectrum disorders. Mediators Inflamm. 2013;2013:935608.PubMedCentralPubMed
70.
Zamora-Ustaran A, Escarcega-Alarcón RO, Garcia-Carrasco M, et al. Antiphospholipid syndrome in Mexican children. Isr Med Assoc J. 2012;14(5):286–9.PubMed
71.
Mazodier K, Arnaud L, Mathian A, et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore). 2012;91(5):251–60.
72.
Berkun Y, Padeh S, Barash J, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum. 2006;55(6):850–5.
73.
Garcia-Carrasco M, Galarza C, Gómez-Ponce M, et al. Antiphospholipid syndrome in Latin American patients: clinical and immunologic characteristics and comparison with European patients. Lupus. 2007;16(5):366–73.PubMed
74.
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019–27.PubMed
75.
Gattorno M, Falcini F, Ravelli A, et al. Outcome of primary antiphospholipid syndrome in childhood. Lupus. 2003;12(6):449–53.PubMed
76.
Gómez-Puerta JA, Martín H, Amigo MC, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore). 2005;84(4):225–30.
77.
Avcin T, Silverman ED. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome. Lupus. 2007;16(8):627–33.PubMed
78.
Andrews A, Hickling P. Thrombosis associated with antiphospholipid antibody in juvenile chronic arthritis. Lupus. 1997;6(6):556–7.PubMed
79.
Caporali R, Ravelli A, Ramenghi B, et al. Antiphospholipid antibody associated thrombosis in juvenile chronic arthritis. Arch Dis Child. 1992;67(11):1384–5.PubMedCentralPubMed
80.
Abend NS, Licht DJ, Spencer CH. Lupus anticoagulant and thrombosis following Henoch-Schonlein purpura. Pediatr Neurol. 2007;36(5):345–7.PubMed
81.
Monastiri K, Selmi H, Tabarki B, et al. Primary antiphospholipid syndrome presenting as complicated henoch-Schonlein purpura. Arch Dis Child. 2002;86(2):132–3.PubMedCentralPubMed
82.
Meglic A, Grosek S, Benedik-Dolnicar M, et al. Atypical haemolytic uremic syndrome complicated by microangiopathic antiphospholipid-associated syndrome. Lupus. 2008;17(9):842–5.
83.
Sherer Y, Livneh A, Levy Y, et al. Dermatomyositis and polymyositis associated with the antiphospholipid syndrome: a novel overlap syndrome. Lupus. 2000;9(1):42–6.
84.
Fung VS, Yiannikas C, Sue CM, et al. Is Sydenham’s chorea an antiphospholipid syndrome? J Clin Neurosci. 1998;5(1):115–8.PubMed
85.
Kiechl-Kohlendorfer U, Ellemunter H, Kiechl S. Chorea as a presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics. 1999;30(2):96–8.PubMed
86.
Caporali R, Ravelli A, De Gennaro F, et al. Prevalence of anticardiolipin antibodies in juvenile arthritis. Ann Rheum Dis. 1991;50(9):599–601.PubMedCentralPubMed
87.
Southwood TR, Roberts-Thomson PJ, Ahern MJ, et al. Autoantibodies in patients with juvenile chronic arthritis and their immediate family relatives. Ann Rheum Dis. 1990;49(12):968–72.PubMedCentral
88.
Gedalia A, Molina IF, Garcia CO, et al. Anticardiolipin antibodies in childhood rheumatic disorders. Lupus. 1998;7(8):551–3.PubMed
89.
Rožiĝ M, Trampuš-Bakija A, Rener-Primec Z, et al. Clinical spectrum and outcome in 100 children with positive antiphospholipid antibodies. Arthritis Rheum. 2008;58:S711–2.
90.
Avcin T, Cimaz R, Meroni PL. Do we need an international consensus statement on classification criteria for the antiphospholipid syndrome in paediatric population? Lupus. 2001;10(12):897–8.PubMed
91.
Cabiedes J, Trejo-Hernandez J, Loredo-Abdala A, et al. Anti-cardiolipin, anticardiolipin plus bovine, or human beta(2)glycoprotein-I and anti-human beta(2)glycoprotein-I antibodies in a healthy infant population. Arch Med Res. 2002;33(2):175–9.PubMed
92.
Vaarala O, Palosuo T, Kleemola M, et al. Anticardiolipin response in acute infections. Clin Immunol Immunopathol. 1986;41(1):8–15.PubMed
93.
Frauenknecht K, Lackner K, von Landenberg P. Antiphospholipid antibodies in pediatric patients with prolonged activated partial thromboplastin time during infection. Immunobiology. 2005;210(10):799–805.PubMed
94.
Martinuc Porobic J, Avcin T, Bozic B, et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clin Exp Immunol. 2005;142(2):377–80.PubMedCentralPubMed
95.
Toplak N, Kveder T, Trampuš-Bakija A, et al. Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev. 2008;8(2):134–8.PubMed
96.
Rapizzi E, Ruffatti A, Tonello M, et al. Correction for age of anticardiolipin antibodies cut-off points. J Clin Lab Anal. 2000;14(3):87–90.PubMed
97.
Siemens HJ, Gutsche S, Brückner S, et al. Antiphospholipid antibodies in children without and in adults with and without thrombophilia. Thromb Res. 2000;98(4):241–7.PubMed
98.
Avcin T, Cimaz R, Meroni PL. Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations. Lupus. 2002;11(1):4–10.PubMed
99.
Cimaz R, Descloux E. Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am. 2006;32(3):553–73.PubMed
100.
Ravelli A, Martini A. Antiphospholipid syndrome in pediatrics. Rheum Dis Clin North Am. 2007;33(3):499–523.PubMed
101.
Becton DL, Stine KC. Transient lupus anticoagulants associated with hemorrhage rather than thrombosis: the hemorrhagic lupus anticoagulant syndrome. J Pediatr. 1997;130(6):998–1000.PubMed
102.
Lee MT, Nardi MA, Hadzi-Nesic J, et al. Transient hemorrhagic diathesis associated with an inhibitor of prothrombin with lupus anticoagulant in a 1½-year-old girl: report of a case and review of the literature. Am J Hematol. 1996;51(4):307–14.PubMed
103.
Yacobovich JR, Uziel Y, Friedman Z, et al. Diffuse muscular haemorrhage as presenting sign of juvenile systemic lupus erythematosus and lupus anticoagulant hypoprothrombinaemia syndrome. Rheumatology (Oxford). 2001;40(5):585–7.
104.
Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349(12):1133–8.PubMed
105.
Orsino A, Schneider R, DeVeber G, et al. Childhood acute myelomonocytic leukemia (AML-M4) presenting as catastrophic antiphospholipid antibody syndrome. J Pediatr Hematol Oncol. 2004;26(5):327–30.PubMed
106.
Gómez-Puerta JA, Cervera R, Espinosa G, et al. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006;35(5):322–32.PubMed
107.
Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification, and treatment. Semin Thromb Hemost. 2008;34(3):282–5.
108.
Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12(7):530–4.PubMed
109.
Cervera R, Font J, Gomez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64(8):1205–9.PubMedCentralPubMed
110.
Manco-Johnson M, Wang M, Goldenberg N, et al. Treatment, survival, and thromboembolic outcomes of thrombotic storm in children. J Pediatr. 2012;161(4):682–8.
111.
Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev. 2010;10(2):74–9.PubMed
112.•
Aguiar CL, Erkan D. Catastrophic antiphospholipid syndrome: how to diagnosis a rare but highly fatal disease. Ther Adv Musculoskelet Dis. 2013;5(6):305–14. A review article summarizing the diagnostic challenges and recently updated diagnostic algorithms for CAPS. PubMedCentralPubMed
113.•
Berman H, Rodríguez-Pintó I, Cervera R, et al. Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the “CAPS Registry”. Autoimmun Rev. 2014;13(2):157–62. A descriptive analysis of pediatric patients from the CAPS registry. PubMed
114.
Alarcon-Segovia D, Boffa MC, Branch W, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus. 2003;12(7):499–503.PubMed
115.
Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206–18.PubMed
116.
Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody–positive individuals. Arthritis Rheum. 2007;56(7):2382–91.PubMed
117.
Wahl DG, Guillemin F, de Maistre E, et al. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus. 1997;6(5):467–73.PubMed
118.
Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev. 2015;14(3):192–200.PubMed
119.
Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010;62(3):863–8.PubMed
120.
Ruiz-Irastorza G, Crowther M, Branch W, et al. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498–509.PubMed
121.
Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006;6(2):98–103.PubMed
122.
Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12(1):70–6.PubMed
123.
Nageswara Rao AA, Arteaga GM, Reed AM, et al. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer. 2009;52(4):536–8.PubMed
124.
Iglesias-Jiménez E, Camacho-Lovillo M, Falcón-Neyra D, et al. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics. 2010;125(6):e1523–8.PubMed
125.•
Berman H, Rodriguez-Pinto I, Cervera R, et al. Rituximab use in the catastrophic syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013;12(11):1085–90. A descriptive analysis of the use of rituximab in pediatric CAPS. PubMed
126.••
Erkan D, Aguiar CL, Andrade D, et al. 14th International congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev. 2014;13(6):685–96. A comprehensive review of the various treatments being used and studied for APS. PubMed
127.
Brandt JT, Triplett DA, Alving B, et al. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74(4):1185–90.PubMed
128.
Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345(20):1444–51.PubMed
129.••
Levine SR, Brey RL, Tilley BC, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576–84. This is a prospective cohort study within the Warfarin versus Aspirin Recurrent Stroke Study (WARSS) [126] that specified in advance APS-related data and sample collection parameters and could be a model for future studies. PubMed
130.
Liu X-W, Pierangeli SS, Barker J, et al. RBC adhesion to cremaster endothelium in mice with abnormal hemoglobin is increased by topical endotoxin. Ann N Y Acad Sci. 1998;850:391–3.PubMed
131.
Westerman M, Green D, Gilman-Sachs A, et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med. 1999;134(4):352–62.PubMed
Metadaten
Titel
Pediatric Antiphospholipid Syndrome
verfasst von
Cassyanne L. Aguiar
Arzu Soybilgic
Tadej Avcin
Barry L. Myones
Publikationsdatum
01.04.2015
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 4/2015
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-015-0504-5

Weitere Artikel der Ausgabe 4/2015

Current Rheumatology Reports 4/2015 Zur Ausgabe

Orphan Diseases (B Manger, Section Editor)

Rheumatic Manifestations of Scurvy

Rheumatoid Arthritis (L Moreland, Section Editor)

Patient Reported Outcomes in Rheumatoid Arthritis Clinical Trials

Antiphospholipid Syndrome (D Erkan, Section Editor)

Difficult Clinical Situations in the Antiphospholipid Syndrome

Surgery and Perioperative Care (CR MacKenzie and SM Goodman, Section Editors)

Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery

Vasculitis (LR Espinoza, Section Editor)

Cogan’s Syndrome and Other Ocular Vasculitides

Vasculitis (L Espinoza, Section Editor)

Antinuclear Antibody (ANA) Testing in Patients Treated With Biological DMARDs: Is It Useful?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise